射频消融作为持续性或复发性Graves病新型治疗方法的两年结果:一项前瞻性研究
这项单臂前瞻性研究在两家三级内分泌外科中心纳入30例持续性/复发性Graves病患者,行超声引导下全甲状腺射频消融。单次射频消融后12个月缓解率60.0%、24个月56.7%;甲状腺总体积是复发的唯一显著相关因素(OR 1.054)。24个月时甲状腺总体积<20 mL者缓解率100%,≥20 mL者35%(P=0.007)。
要点
- 单次射频消融后24个月疾病缓解率为56.7%,12个月为60.0%。
- 24个月时甲状腺总体积<20 mL者缓解率100%,≥20 mL者35%(P=0.007)。
核心结论
- 在高度选择的复发性Graves病患者中(以甲状腺较小者为主),单次射频消融可能实现疾病缓解。
- 较小的甲状腺总体积可能是射频消融后疾病缓解的有利因素。
- 作者指出该研究结果需通过长期临床试验确认。
研究设计与样本
- 单臂前瞻性研究,从两家三级内分泌外科中心连续纳入年龄≥18岁、需抗甲状腺药物治疗的持续性/复发性Graves病患者。
- 排除压迫性甲状腺肿、疑似甲状腺恶性肿瘤、中重度Graves眼病、倾向手术或放射性碘治疗者以及妊娠者。
- 符合条件者接受超声引导下对整个甲状腺腺体的射频消融,术后停用抗甲状腺药物,每两个月监测甲状腺功能。
- 主要结局为单次射频消融后24个月随访时的疾病缓解率,定义为不使用抗甲状腺药物情况下生化甲状腺功能正常或甲状腺功能减退;次要结局为并发症发生率。
- 共考虑100例患者,其中30例(30.0%)符合条件并接受射频消融;大多数为女性(93.3%);中位甲状腺总体积为23 mL(15.9-34.5);全部完成24个月随访。
主要发现
- 单次射频消融后疾病缓解率12个月为60.0%,24个月为56.7%。
- 射频消融后复发的13例患者中,9例(69%)所需抗甲状腺药物剂量低于射频消融前;2例接受手术且无并发症。
- 24个月时,甲状腺总体积<20 mL的9例患者中100%实现疾病缓解,甲状腺总体积≥20 mL者中35%实现缓解(P=0.007)。
- 射频消融后未发生声带麻痹、皮肤烧伤、血肿或甲状腺风暴。
关键数值与推荐
- 疾病缓解定义为不使用抗甲状腺药物情况下生化甲状腺功能正常或甲状腺功能减退。
- 24个月时甲状腺总体积<20 mL者缓解率100%(9例),≥20 mL者缓解率35%(P=0.007)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出该研究结果需通过长期临床试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: Graves' disease (GD) is the most common cause of hyperthyroidism. Antithyroid drugs (ATDs) are the first-line treatment, but when discontinued, >50% of patients experience relapses. Conventional definitive treatment options include surgery and radioiodine therapy (RAI), each with its own disadvantages. Radiofrequency ablation (RFA) achieved promising short-term remission rates in a previous pilot study. The current study reports our experience of using RFA to treat relapsed GD in the largest cohort of patients with a longer follow-up period. Methods: This single-arm prospective study recruited consecutive patients aged ≥18 with persistent/relapsed GD requiring ATD from two tertiary endocrine surgery centers. Those with compressive goiter, suspected thyroid malignancy, moderate-to-severe Graves' ophthalmopathy, preference for surgery/RAI, or pregnancy were excluded. Eligible patients received ultrasound-guided RFA to the entire bulk of the thyroid gland. ATDs were discontinued afterward, and thyroid function tests were monitored bimonthly. The primary outcome was the disease remission rate at 24 months follow-up after single-session RFA, defined as being biochemically euthyroid or hypothyroid without ATD. Secondary outcomes were complication rates. Results: Of the 100 patients considered, 30 (30.0%) patients were eligible and received RFA. Most were female patients (93.3%). The median total thyroid volume was 23 mL (15.9-34.5). All completed 24 months follow-up. After single-session RFA, disease remission rates were 60.0% at 12 months and 56.7% at 24 months. Among the 13 patients with relapse after RFA, 9 (69%) required a lower ATD dose than before RFA; 2 received surgery without complications. Total thyroid volume was the only significant factor associated with relapse after RFA (odds ratio 1.054, confidence interval 1.012-1.099, p = 0.012). At 24 months, RFA led to disease remission in 100% of the 9 patients with a total thyroid volume <20 mL and 35% of patients with a total thyroid volume ≥20 mL (p = 0.007). There was no vocal cord palsy, skin burn, hematoma, or thyroid storm after RFA. Conclusions: In a highly selected group of patients with relapsed GD and predominantly small thyroid glands, single-session RFA may achieve disease remission. Smaller total thyroid volume may be a favorable factor associated with disease remission after RFA. The results of this study need to be confirmed with a long-term clinical trial. Clinical Trial Registration: This study is registered at www.clinicaltrial.gov with identifier NCT06418919.
引用
- Fung MHM, Luk Y, Yuen KKW, et al. The Two-Year Results of Using Radiofrequency Ablation as a Novel Treatment for Persistent or Relapsed Graves' Disease: A Prospective Study. Thyroid. 2024. PMID: 38836419. doi:10.1089/thy.2024.0177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。